OP129 The Use Of A Text-Mining Screening Tool For Systematic Review Of Treatments For Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Author(s):  
Niamh Carey ◽  
Marie Harte ◽  
Laura McCullagh

IntroductionHuman screening of title and abstracts in a systematic literature review (SLR) is labor intensive and time-consuming. In many instances, thousands of citations may be retrieved; the vast majority excluded upon screening. Text-mining semi-automates and accelerates screening by identifying patterns in relevant and irrelevant citations, as labelled by the screener. One such text-mining tool, Abstrackr, uses an algorithm within an active-learning framework to predict the likelihood of citations being relevant. The objective of this study was to assesses the performance of Abstrackr for title and abstract screening in an SLR of treatments for relapsed/refractory diffuse large B-cell lymphoma.MethodsCitations identified from searches of electronic databases were imported to Abstrackr. An investigator-selected database of terms indicating relevance of title and abstract to the research question were uploaded. These terms were partly informed by the SLR inclusion/exclusion criteria. Citations deemed most relevant by Abstrackr were screened first (screening prioritization). Screening was carried out until a maximum prediction score of 0.4 or less, based on previous experience in the literature, was reached. Remaining citations were deemed unlikely to be relevant and did not undergo screening (screening truncation). Separately, a single-human screener screened all citations using Covidence.ResultsA total of 7,723 citations and 154 initial terms were uploaded to Abstrackr. Of these citations, 2,572 (33 percent) were screened before a prediction score of 0.39 was reached. Compared to single-human screening (conducted on all citations), the workload saving associated with Abstrackr was 5 days. A total of 451 (6 percent) citations proceeded to full-text screening; ten (0.1 percent) were included in the final evidence base. No citations predicted to be irrelevant by Abstrackr were included in the final evidence base.ConclusionsText-mining tools such as Abstrackr have the potential to reduce workload associated with title and abstract screening, without missing relevant citations.

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.


Sign in / Sign up

Export Citation Format

Share Document